Morningstar
•
May 22, 2026
Eli Lilly and Company: Eli Lilly Earnings: Mounjaro/Zepbound's Massive Volume Growth More Than Counters Price Pressure
Summary
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog,
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Costco Wholesale Corp
May 29, 2026
•
COST
Market Update: AIG, COST
May 29, 2026
•
COST, AIG
Analyst Report: AbbVie Inc.
May 28, 2026
•
ABBV
The Argus Sustainable Growth Theme Model Portfolio
May 28, 2026
•
TT, DE, GOOGL, NDAQ, AAPL, AVGO, JPM, ADI, MRK, JNJ, TXN, MSFT, TFC, GLW, MA, LLY, TRV, SPGI, GE, NVDA, NOC, KO, KMI, AEP, GS, ECL, TMUS, ETN, AMZN, WMT
Analyst Profile
Karen Andersen
Sector Strategist
Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is responsible for biotechnology research.Before joining Morningstar in 2005, Andersen received a master’s degree in business administration from Rice University, where she served as senior healthcare analyst for the M.A. Wright Fund and earned the distinction of Jones Scholar. She has scientific research experience in both academia (at Rice University and the University of Queensland in Australia) and industry (at Lexicon Genetics and a subsidiary of Genzyme).Andersen also holds a bachelor’s degree in biochemistry from Rice University, where she graduated magna cum laude. She is a member of Phi Beta Kappa and holds the Chartered Financial Analyst® designation. She ranked first in the biotechnology industry, and had the highest score overall, in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.
